Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics, Inc. (STIM) reported an insider transaction by a director. On 10/20/2025, the director acquired 6,410 shares of common stock via a restricted stock unit (RSU) grant that vested immediately and was elected in lieu of a cash retainer under the non-employee directors compensation plan. The RSU acquisition price was $0, with each RSU representing one share.
Following the transaction, the director beneficially owned 1,512,798 shares directly. The filing also lists indirect beneficial ownership of 516,084 shares through Greybrook Health Inc. and 2,042 shares through Greybrook Realty Partners Inc.
Madryn and affiliated funds report beneficial ownership of 20,737,061 shares of Neuronetics, Inc. common stock, representing approximately 31.4% of the outstanding shares based on 66,124,820 shares outstanding as of July 31, 2025. The Schedule 13D/A amends a prior filing and consolidates holdings across multiple Madryn entities and advisers while clarifying that Madryn and the advisors may be deemed to have indirect beneficial ownership through their advisory and partnership roles.
The amendment also discloses executed sales: MHP II, MHP II Cayman and MSO sold specified tranches of shares under Rule 144 at about $3.72 per share, and it notes that Covered Persons generally disclaim beneficial ownership except that Avinash Amin holds 12,500 shares (<1%) directly.
Neuronetics, Inc. (STIM) filed a Form 144 reporting a proposed sale of 2,925,554 common shares, with an aggregate market value of $10,883,060.88. The filing lists Morgan Stanley Smith Barney LLC as the broker and indicates the shares are to be sold on NASDAQ with an approximate sale date of 08/08/2025.
The notice shows the shares were acquired on 12/10/2024 in connection with a Merger/Acquisition from the issuer and were paid for in cash. The filer reports nothing to report for securities sold in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.
Neuronetics, Inc. (STIM) filed a Form 144 reporting a proposed sale of 192,806 common shares with an aggregate market value of $717,238.32. The filing states the sale is expected on or about 08/08/2025 on NASDAQ and lists Morgan Stanley Smith Barney LLC as the broker. The shares were acquired on 12/10/2024 in a merger/acquisition transaction from the issuer and were paid for in cash. The filing reports 66,124,820 shares outstanding and notes Nothing to Report for sales in the past three months.
Neuronetics, Inc. (Form 144) filed a notice proposing the sale of 381,640 shares of Common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 08/08/2025 and an aggregate market value of $1,419,700.80 against 66,124,820 shares outstanding. The shares to be sold were acquired from the issuer in a merger/acquisition on 12/10/2024.
The filing shows the purchase was paid in cash on 12/10/2024, reports no securities sold in the past three months, and includes the required signer representation that the seller is not aware of undisclosed material adverse information about the issuer. The notice identifies the executing broker and the exchange but provides no further financial results or forward guidance.
Neuronetics (STIM) Q2-25 10-Q snapshot
Revenue jumped 132% YoY to $38.1 M as the December 2024 Greenbrook acquisition added clinic revenue (61% of sales). Treatment-session revenue grew 32% while NeuroStar device sales fell 13%. Gross margin compressed to 46.6% from 74.0% given the lower-margin clinic mix.
Operating loss improved slightly to $8.1 M, but higher interest cost (SOFR+7%) left net loss to shareholders at $10.1 M (-$0.15/sh); share count more than doubled after a February 2025 secondary offering that raised $18.9 M net. Six-month revenue rose 107% to $70.1 M, with a net loss of $22.8 M.
Cash & equivalents fell to $11.0 M (plus $6.5 M restricted) after a $20.5 M operating cash burn YTD. Long-term debt remains $55.5 M under the Perceptive facility, maturing 2029; leverage covenants commence Q1-26. Equity totals $31.5 M.
Management expects available cash and projected sales to fund operations for at least 12 months and anticipates cost synergies from Greenbrook.
Neuronetics, Inc. (STIM) filed an 8-K on 5-Aug-2025 announcing Amendment No. 3 to its July 2024 Credit Agreement with Perceptive Credit Holdings IV.
- Immediate liquidity: the amendment allows the company to draw a $10 million Tranche 2A term loan on the execution date (1-Aug-2025).
- Covenant relief: the minimum cash/liquidity requirement is reduced to $2 million through 30-Sep-2026, giving the company additional flexibility.
- Equity sweetener: Perceptive receives a warrant for 225,000 common shares; exercise terms were not disclosed in the filing.
Items 2.02 and 7.01 merely furnish (not file) the company’s Q2-25 earnings press release (Ex. 99.1) and an investor presentation (Ex. 99.2); no financial figures are included in this document.
Exhibits disclosed are: 10.1 (Amendment), 99.1 (press release), 99.2 (presentation) and 104 (iXBRL cover).